Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection NEW ENGLAND JOURNAL OF MEDICINE Shafer, R. W., Smeaton, L. M., Robbins, G. K., De Gruttola, V., Snyder, S. W., D'Aquila, R. T., JOHNSON, V. A., Morse, G. D., Nokta, M. A., Martinez, A. I., Gripshover, B. M., Kaul, P., Haubrich, R., Swingle, M., McCarty, S. D., Vella, S., Hirsch, M. S., Merigan, T. C., Fischl, M., Pollard, R., Dube, M., Pettinelli, C., Delapenha, R., Putnam, B., Klebert, M., Testa, M., Chiesi, A., Tomino, C., Deeks, S., Nevin, T., Levin, J., French, V., Fennell, O., Stevens, M., Grosso, R., Dusak, B., Hodder, S., Tolson, J., Brothers, C., Leavitt, R., Manion, D., Ruiz, N., Morrisey, K., Becker, M., Quart, B., Jennings, C., Gedeon, L., Dascomb, S., Cooper, M., Murphy, M., Blakelock, K., Doolan, A. 2003; 349 (24): 2304-2315

Abstract

It is unclear whether therapy for human immunodeficiency virus type 1 (HIV-1) should be initiated with a four-drug or two sequential three-drug regimens.In this multicenter trial we compared initial therapy involving four-drug regimens containing efavirenz and nelfinavir in combination with either didanosine and stavudine or zidovudine and lamivudine with therapy involving two consecutive three-drug regimens the first of which contained either efavirenz or nelfinavir.A total of 980 subjects were followed for a median of 2.3 years. There was no significant difference in the occurrence of regimen failures between the group that received the four-drug regimen containing didanosine, stavudine, nelfinavir, and efavirenz and the groups that received the three-drug regimens beginning with didanosine, stavudine, and nelfinavir (hazard ratio for regimen failure, 1.24) or didanosine, stavudine, and efavirenz (hazard ratio, 1.01). There was no significant difference between the group that received the four-drug regimen containing zidovudine, lamivudine, nelfinavir, and efavirenz and the groups that received the three-drug regimens beginning with zidovudine, lamivudine, and nelfinavir (hazard ratio, 1.06) or zidovudine, lamivudine, and efavirenz (hazard ratio, 1.45). A four-drug regimen was associated with a longer time to the first regimen failure than the three-drug regimens containing didanosine, stavudine, and nelfinavir (hazard ratio for a first regimen failure, 0.55); didanosine, stavudine, and efavirenz (hazard ratio, 0.63); or zidovudine, lamivudine, and nelfinavir (hazard ratio, 0.49), but not the three-drug regimen containing zidovudine, lamivudine, and efavirenz (hazard ratio, 1.21).There was no significant difference in the duration of successful HIV-1 treatment between a single four-drug regimen and two consecutive three-drug regimens. Among these treatment strategies, initiating therapy with the three-drug regimen of zidovudine, lamivudine, and efavirenz is the optimal choice.

View details for Web of Science ID 000187125000006

View details for PubMedID 14668456